448906-42-1,
ITE,
methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate,
Methyl 2-(1H-indole-3-carbonyl)-1,3-thiazole-4-carboxylate,
2-(1H-INDOL-3-YLCARBONYL)-4-THIAZOLECARBOXYLIC ACID METHYL ESTER,
AK116400,
AHR agonist,
AC1NG3SQ,
The endogeneous AHR ligand,
SCHEMBL422944,
Aryl hydrocarbon receptor ligand,
CHEMBL1324296,
CHEBI:93059,
CTK8E8656,
KS-00000GGE,
DTXSID70405386,
HMS3268G16,
BCP17758,
EX-A1251,
ZINC8205850,
6191AB,
MFCD06411597,
AKOS016010400,
CS-5141,
RTX-011599,
SB17198,
NCGC00159529-01,
NCGC00159529-02,
NCGC00159529-03,
ACM448906421,
AJ-57359,
HY-19317,
AX8135481,
DB-023618,
FT-0732784,
A22724,
BRD-K60298136-001-01-7,
2-(1'H-Indole-3'-carbonyl)-thiazole-4-carboxylic acid,
2-(1'H-indole-37-carbonyl)-thiasole-4-carboxylic acid methyl ester,
4-Thiazolecarboxylic acid, 2-(1H-indol-3-ylcarbonyl)-, methyl ester,
ITE (cancer),
D07IZS,
C14H10N2O3S,
KDDXOGDIPZSCTM-UHFFFAOYSA-N,
ITE (cancer), AhR Pharmaceuticals,
CID4668801,
A8615,
Methyl2-(1H-indole-3-carbonyl)thiazole-4-carboxylate,
Aryl hydrocarbon receptor (AhR) agonist (cancer), AhR Pharmaceuticals,